Flag of the European Union EU Clinical Trials Register Help

Clinical trials for COVID-19 AND vaccine AND pregnant

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: COVID-19 AND vaccine AND pregnant. Displaying page 1 of 1.
    EudraCT Number: 2021-002327-38 Sponsor Protocol Number: NL77670.029.21 Start Date*: 2021-05-26
    Sponsor Name:Academic Medical Center
    Full Title: PREGCOVAC-19: the follow up of pregnant women who received COVID-19 vaccination in the Dutch national vaccination program
    Medical condition: Pregnant women aged ≥ 18 years who are scheduled for COVID-19 vaccination within the Dutch national vaccination program with any of the currently or future available vaccines that are used for preg...
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    21.1 100000004868 10036586 Pregnant LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000893-27 Sponsor Protocol Number: SJ2021016 Start Date*: 2021-04-27
    Sponsor Name:AZ Sint-Jan Brugge-Oostende AV
    Full Title: COVID-19: study to detect transfer of SARS-Cov-2 antibodies in breastmilk
    Medical condition: pregnancy lactating mothers
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000440-22 Sponsor Protocol Number: Version17032021 Start Date*: 2021-03-25
    Sponsor Name:Universiteit Antwerpen
    Full Title: Vaccination against COVID-19 in Pregnant and Lactating Women in Belgium
    Medical condition: Vaccine responses to COVID19 vaccines administered in pregnant and lactating women
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004272-17 Sponsor Protocol Number: CLO-SCB-2019-003 Start Date*: 2021-03-25
    Sponsor Name:Clover Biopharmaceuticals AUS Pty Ltd
    Full Title: A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (S...
    Medical condition: SARS-CoV-2-mediated COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000548-23 Sponsor Protocol Number: UKE-SARS-COV-2-ST Start Date*: 2021-07-07
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: A multi-center, phase Ib trial to assess the safety, tolerability and immunogenicity of the candidate vaccine MVA-SARS-2-ST in adults
    Medical condition: This study is designed to evaluate the safety, tolerability and reactogenicity of intramuscular dose administrations of: -3 dose levels of the MVA-SARS-2-ST vaccine in healthy SARS-CoV-2 seronegati...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003370-41 Sponsor Protocol Number: VAT00002 Start Date*: 2021-08-23
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines with AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SA...
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-002502-75 Sponsor Protocol Number: P-pVAC-SARS-CoV-2 Start Date*: 2020-11-26
    Sponsor Name:University Hospital Tuebingen
    Full Title: P-pVAC-SARS-CoV-2: Phase I single-center safety and immungenicity trial of multi-peptide vaccination to prevent COVID-19 infection in adults
    Medical condition: healthy subjects obtaining a potential vaccine for COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005576-35 Sponsor Protocol Number: CP-PRO-CoVLP-021 Start Date*: 2021-05-06
    Sponsor Name:Medicago R&D Inc.
    Full Title: A Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years o...
    Medical condition: Covid-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003734-20 Sponsor Protocol Number: COV-1/2-01 Start Date*: 2021-02-03
    Sponsor Name:Takis S.r.l.
    Full Title: A Phase I/II study to assess the safety and immunogenicity of COVID-eVax, a candidate plasmid DNA vaccine for COVID-19, in healthy adult volunteers.
    Medical condition: COVID-19 prevention.
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003102-26 Sponsor Protocol Number: HIV-CORE007 Start Date*: 2021-07-14
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Therapeutic vaccination: A Phase I/II Randomized, Placebo-Controlled Trial of ChAdOx1.tHIVconsvX prime-MVA.tHIVconsvX Boost Vaccination Regimen in Early-treated durably-controlling HIV-1 positive A...
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10008919 Chronic HIV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005330-14 Sponsor Protocol Number: VAC31518COV2004 Start Date*: 2021-04-06
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: An Open-label, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants.
    Medical condition: Healthy Pregnant Volunteers (Prevention of SARS-CoV-2-mediated COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000509-26 Sponsor Protocol Number: ANRS0002S Start Date*: 2021-02-24
    Sponsor Name:Inserm-ANRS
    Full Title: A phase II trial assessing immunogenicity and safety of COVID-19 mRNA Vaccine BNT162b2 in adult volunteers with no history of SARS CoV-2 infection administered with two doses of vaccine (D1-D29) an...
    Medical condition: Healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084464 COVID-19 immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005194-77 Sponsor Protocol Number: Matimmunestudyversion2 Start Date*: 2021-10-26
    Sponsor Name:University of Antwerp
    Full Title: The optimal timing of vaccination in pregnancy: a multi-dimensional mechanistic approach to measure immune responses in pregnant women
    Medical condition: humoral and cellular immune responses to pertussis vaccine during pregnancy
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001070-38 Sponsor Protocol Number: B-pVAC-SARS-CoV-2 Start Date*: 2021-06-21
    Sponsor Name:University Hospital Tuebingen
    Full Title: B-pVAC-SARS-CoV-2: Phase I/II multi-center safety and immungenicity trial of multi-peptide vaccination to prevent COVID-19 infection in adults with B-cell/antibody deficiency
    Medical condition: Adults with congenital or acquired B cell/antibody deficiency
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005444-35 Sponsor Protocol Number: C4591015 Start Date*: 2021-04-15
    Sponsor Name:BioNTech SE
    Full Title: A PHASE 2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE (BNT162b2) AGAINST COVID-19 IN HEAL...
    Medical condition: Protection against COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: In utero, Under 18, Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-000692-39 Sponsor Protocol Number: IVY Start Date*: 2023-06-19
    Sponsor Name:Amsterdam University Medical Center
    Full Title: Safety, tolerability and immunogenicity of intradermal mRNA SARS-CoV2 vaccination in patients with Fibrodysplasia Ossificans Progressiva
    Medical condition: Fibrodyplasia Ossificans Progressiva (FOP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10068715 Fibrodysplasia ossificans progressiva PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003205-29 Sponsor Protocol Number: CAP2022-1 Start Date*: 2023-02-23
    Sponsor Name:Aphaia Pharma US LLC
    Full Title: A Phase II, randomized, placebo – controlled crossover proof-of-concept study to evaluate efficacy and safety of distal jejunal-release dextrose beads formulation (APHD-012) in subjects with a path...
    Medical condition: Subjects with a pathological Oral Glucose Tolerance Test (OGTT)
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004861 10065542 Prediabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005989-34 Sponsor Protocol Number: 034B20 Start Date*: 2022-08-31
    Sponsor Name:Aphaia Pharma AG
    Full Title: A Phase II, randomized, double-blind, placebo-controlled, parallel-group proof-of-concept study to evaluate efficacy and safety of distal jejunal-release dextrose (Aphaia technology, AT) in obese s...
    Medical condition: Obesity with/without associated endocrine and/or metabolic conditions and/or hypertension and/or NASH and/or NAFL with/without fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003307-16 Sponsor Protocol Number: OMT28-C0203 Start Date*: 2023-04-18
    Sponsor Name:OMEICOS Therapeutics GmbH
    Full Title: A Phase 2a Safety, Tolerability, and Pharmacodynamic Study of OMT-28 in PMD patients with myopathy and/or cardiomyopathy and inflammation (PMD-OPTION)
    Medical condition: Primary Mitochondrial Disease (PMD)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10010331 - Congenital, familial and genetic disorders 10052641 Mitochondrial DNA mutation PT
    22.0 10010331 - Congenital, familial and genetic disorders 10052641 Mitochondrial DNA mutation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004958-42 Sponsor Protocol Number: MOM-M281-003 Start Date*: 2019-01-11
    Sponsor Name:Momenta Pharmaceuticals, Inc.
    Full Title: A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease ...
    Medical condition: Early onset Severe Hemolytic Disease of the fetus and newborn (HDFN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10019512 Hemolytic disease due to Rh isoimmunization of fetus or newborn LLT
    Population Age: In utero, Under 18, Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) SE (Completed) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 14:56:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA